Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.